3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
2
Breast Neoplasms
2
Recurrent Squamous Cell Lung Carcinoma
1
Non-small Cell Lung Cancer Metastatic
1
Neoplasms
1
Multiple Myeloma
1
Lymphoma
1
Lung Neoplasms
1
Hematologic Neoplasms
1
FGFR1 Gene Amplification
1
Carcinoma, Squamous Cell
1
Adenocarcinoma
1
Interventions
1-(1-(imidazo(1,2-a)pyridin-6-yl)ethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-(1,2,3)triazolo(4,5-b)pyrazine
2
vistusertib
1
vandetanib
1
telomerase reverse transcriptase p572Y, human
1
spartalizumab
1
pembrolizumab
1
olaparib
1
durvalumab
1
capivasertib
1
Vinorelbine
1
Ramucirumab
1
Pemetrexed
1
Paclitaxel
1
Gemcitabine
1
Erlotinib Hydrochloride
1
Docetaxel
1
Carboplatin
1
Bevacizumab
1
AZD4547
1
AZD 8931
1
AZD 6244
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
Non-small Cell Lung Cancer Metastatic
×
AZD4547
×
Clear all
NCT02117167
2024-01-10
SAFIR02_Lung
UNICANCER
Phase 2
Completed
999 enrolled